STAAR Surgical Company: Form 10-K Summary
Reporting period: Fiscal year ended January 2, 2015, including the fourth quarter of fiscal 2014. The request metadata references “2013 Q4,” but the provided filing is the 2014 Form 10-K. Fiscal 2014 comprised 52 weeks versus 53 weeks in fiscal 2013.
Business Context
STAAR designs, manufactures and sells implantable lenses and delivery systems for ophthalmic surgery. Its principal products are Visian implantable Collamer lenses (ICLs) for refractive surgery and intraocular lenses (IOLs) for cataract surgery. The company sells in more than 60 countries, with approximately 85% of fiscal 2014 sales generated outside the United States, and operates as one ophthalmic surgical products segment.
In June 2014, STAAR completed the planned consolidation of substantially all manufacturing in Monrovia, California, while retaining manufacturing capabilities in Switzerland. The transition contributed to manufacturing challenges, lower yields and product backlogs late in the year.
Financial Performance and Liquidity
| Metric | FY 2014 | FY 2013 | Change |
|---|---|---|---|
| Net sales | $75.0 million | $72.2 million | +3.8% |
| Gross profit | $48.8 million | $50.3 million | -3.0% |
| Gross margin | 65.1% | 69.7% | -460 basis points |
| Operating income (loss) | $(8.0) million | $0.7 million | Declined to loss |
| Net income (loss) | $(8.4) million | $0.4 million | Declined to loss |
| Diluted loss per share | $(0.22) | $0.01 | Declined |
| Cash flow from operations | $(8.0) million | $3.4 million | Declined |
| Capital expenditures | $4.1 million | $3.4 million | Increased |
- ICL sales were $44.0 million, or 58.7% of total sales, down 0.2% year over year.
- IOL sales were $24.3 million, or 32.5% of total sales, up 0.8%.
- Other surgical product sales increased 67.9% to $6.6 million, primarily from injector parts sold to a third-party manufacturer. These products carry lower margins.
- Research and development expense increased 84.3% to $12.4 million, or 16.5% of sales, including FDA remediation and advisory-panel costs.
- Cash and cash equivalents were $13.0 million at year-end, down from $23.0 million. Working capital was $28.5 million versus $31.7 million.
- Year-end inventory increased to $15.7 million from $12.5 million, and inventory reserves increased materially, partly due to Toric ICL inventory prepared for a prospective U.S. launch.
- Total debt consisted primarily of a $4.2 million Japanese yen-denominated line of credit. A $1.0 million Swiss credit facility was fully available, with no borrowings outstanding. The company reported compliance with its credit covenants.
- Total liabilities were $21.8 million and stockholders’ equity was $37.1 million. Pension plans were underfunded by approximately $3.1 million.
Material Changes Versus the Prior Comparable Period
- Revenue growth slowed substantially from 13.2% in fiscal 2013 to 3.8% in fiscal 2014. ICL growth, a principal driver in 2013, was essentially flat in 2014.
- Gross margin fell from 69.7% to 65.1% because of manufacturing-transition costs, higher ICL manufacturing costs, increased inventory provisions and a greater mix of lower-margin injector-part sales.
- The company moved from modest profitability to an $8.4 million net loss. Higher general and administrative, marketing and selling, and research and development expenses contributed to the decline.
- Operating cash flow shifted from a $3.4 million source to an $8.0 million use, driven by the net loss and increased working capital, particularly inventory.
- Foreign currency movements reduced fiscal 2014 sales by approximately $1.6 million and produced a $0.9 million foreign-currency transaction loss.
- Manufacturing issues caused fourth-quarter ICL and Toric ICL backlogs and a voluntary hold on more than 2,000 ICLs. Management estimated approximately $1.0 million of fourth-quarter revenue impact.
Guidance, Outlook, Risks and Unusual Items
- Management expected revenue growth over the following 12 months, driven primarily by ICLs and preloaded acrylic IOLs, with a related improvement in gross margin and earnings. No specific revenue or earnings range was provided.
- Management expected to spend approximately $4 million in fiscal 2015 on FDA remediation activities, which were expected to continue through 2016. Research and development investment was expected to be approximately 12% of sales in 2015.
- Management expected the ICL backlog to return to customary levels by the end of the first or second quarter of 2015, but warned that unresolved manufacturing challenges could adversely affect results.
- The FDA issued a May 2014 warning letter concerning cGMP deficiencies involving design controls, software validation, ICL complaint trending and shelf-life data. A February 2015 FDA-483 identified ten additional observations, primarily concerning design-change controls, validation, documentation and environmental monitoring.
- The Toric ICL U.S. PMA supplement remained pending despite favorable March 2014 advisory-panel votes. The company could not predict when, or whether, FDA approval would be granted.
- The SEC began an informal inquiry in July 2014 regarding compliance with U.S. securities laws and FDA-related disclosures. The company was cooperating.
- A putative securities class action alleged misleading statements and omissions regarding regulatory issues at the Monrovia facility. The company stated that it believed the allegations were without merit and intended to defend the case; the potential loss was not estimable from the filing.
- Key ongoing risks include dependence on the Monrovia facility, single-source materials, regulatory enforcement or recalls, foreign currency exposure, international distributors, elective-procedure demand, reimbursement pressure on IOLs, patent expirations and limited operating cash generation.
- A fourth-quarter tax benefit of approximately $1.4 million, principally related to Swiss operations and tax-ruling discussions, reduced the reported tax expense. The company also had approximately $130.8 million of U.S. federal net operating loss carryforwards, subject to realization and potential Section 382 limitations.
Investor Verification Checklist
- Verify whether manufacturing yields, ICL backlog and product availability improved as projected during the first half of fiscal 2015.
- Assess the status and financial impact of corrective actions related to the 2014 FDA warning letter and 2015 FDA-483.
- Confirm the timing and probability of U.S. Toric ICL approval and any associated commercialization costs.
- Reconcile cash use, inventory growth and inventory reserves against subsequent operating cash flow and gross-margin performance.
- Review the renewal and repayment status of the $4.2 million Japanese credit facility and the company’s ongoing liquidity needs.
- Monitor the SEC inquiry and securities litigation for potential financial, disclosure or reputational consequences.
- Evaluate whether the planned manufacturing consolidation and tax strategy deliver the expected margin improvement and U.S. tax-loss utilization.